Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
Acute respiratory distress syndrome
COVID-19
Cell therapy
Cytokine release syndrome
Extracellular vesicles
Mesenchymal stromal cells
SARS-CoV-2
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
26 06 2023
26 06 2023
Historique:
received:
19
11
2022
accepted:
15
06
2023
medline:
28
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients. COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × 10 A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14-1.11; P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005-1.26; P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041). MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073 .
Sections du résumé
BACKGROUND AND AIMS
The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients.
MATERIALS AND METHODS
COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × 10
RESULTS
A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14-1.11; P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005-1.26; P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041).
CONCLUSION
MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073 .
Identifiants
pubmed: 37365605
doi: 10.1186/s13287-023-03402-8
pii: 10.1186/s13287-023-03402-8
pmc: PMC10294333
doi:
Banques de données
IRCT
['IRCT20200217046526N2']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Informations de copyright
© 2023. The Author(s).
Références
J Thorac Dis. 2013 Jun;5(3):326-34
pubmed: 23825769
Cell J. 2022 Jul 27;24(7):424-426
pubmed: 36043411
Eur Heart J. 2021 Feb 11;42(6):559-560
pubmed: 33206948
Expert Rev Gastroenterol Hepatol. 2022 Jan;16(1):1-3
pubmed: 34919489
Int J Epidemiol. 2021 May 17;50(2):420-429
pubmed: 33683344
Emerg Med Int. 2020 Sep 23;2020:1930405
pubmed: 33029403
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
Clin Transl Med. 2021 Feb;11(2):e297
pubmed: 33634996
Curr Probl Cardiol. 2020 Aug;45(8):100618
pubmed: 32439197
J Mol Med (Berl). 2020 Jun;98(6):789-803
pubmed: 32494931
Stem Cell Res Ther. 2022 Jun 17;13(1):257
pubmed: 35715852
Signal Transduct Target Ther. 2020 Aug 27;5(1):172
pubmed: 32855385
J Mol Med (Berl). 2021 Feb;99(2):303-310
pubmed: 33392632
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
J Thromb Thrombolysis. 2021 Apr;51(3):595-607
pubmed: 33586113
Stem Cell Res Ther. 2022 Aug 12;13(1):410
pubmed: 35962458
Stem Cells Transl Med. 2021 May;10(5):660-673
pubmed: 33400390
BMB Rep. 2020 Aug;53(8):400-412
pubmed: 32731913
Stem Cell Res Ther. 2022 Mar 24;13(1):124
pubmed: 35321737
Stem Cell Res Ther. 2022 Mar 7;13(1):96
pubmed: 35255966
Clinics (Sao Paulo). 2021 May 17;76:e2604
pubmed: 34008772
Adv Drug Deliv Rev. 2017 Dec 1;122:2-19
pubmed: 27916504
Int Immunopharmacol. 2021 Oct;99:107961
pubmed: 34426106
Stem Cells Transl Med. 2021 Sep;10(9):1279-1287
pubmed: 34102020
Stem Cell Res Ther. 2022 Mar 21;13(1):122
pubmed: 35313959
Iran J Allergy Asthma Immunol. 2022 Dec 24;21(6):677-686
pubmed: 36640059
Life Sci. 2021 Aug 1;278:119510
pubmed: 33865879
Indian J Hematol Blood Transfus. 2020 Oct;36(4):616-626
pubmed: 32837053
Cell Res. 2021 Dec;31(12):1244-1262
pubmed: 34702946
Cytokine Growth Factor Rev. 2022 Dec;68:25-36
pubmed: 35843774
Nat Rev Drug Discov. 2010 Apr;9(4):325-38
pubmed: 20305665
Cell Transplant. 2021 Jan-Dec;30:9636897211024942
pubmed: 34180719
Int J Prev Med. 2022 Oct 05;13:125
pubmed: 36452476
Cell J. 2021 Jul;23(2):247-250
pubmed: 34096226
Stem Cell Res Ther. 2021 Jan 29;12(1):91
pubmed: 33514427
Stem Cell Rev Rep. 2021 Feb;17(1):71-93
pubmed: 32895900
Stem Cells Transl Med. 2022 Nov 18;11(11):1103-1112
pubmed: 36181766
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Thromb Haemost. 2020 Nov;120(11):1524-1535
pubmed: 32679593
J Thromb Thrombolysis. 2021 Apr;51(3):663-674
pubmed: 33098540
Drug Dev Ind Pharm. 2021 Sep;47(9):1353-1361
pubmed: 34666567
Drug Saf. 2021 Sep;44(9):929-938
pubmed: 34339037
Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90
pubmed: 34387172
Front Immunol. 2021 Aug 10;12:720363
pubmed: 34447386
Health Sci Rep. 2022 Apr 13;5(3):e550
pubmed: 35509400
Immun Inflamm Dis. 2021 Jun;9(2):399-405
pubmed: 33465283
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Signal Transduct Target Ther. 2021 Sep 8;6(1):339
pubmed: 34497264
Expert Rev Respir Med. 2020 Nov;14(11):1149-1163
pubmed: 32734777
Gene Rep. 2022 Mar;26:101448
pubmed: 34869941
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Thromb Res. 2021 May;201:23-29
pubmed: 33631519
Emerg Med J. 2021 Jul;38(7):543-548
pubmed: 34021028
JAMA. 2021 Nov 16;326(19):1895-1897
pubmed: 34705039
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Ann Acad Med Singap. 2020 Jan;49(3):108-118
pubmed: 32200400
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
EBioMedicine. 2022 Mar;77:103920
pubmed: 35279630
Int J Antimicrob Agents. 2020 Dec;56(6):106208
pubmed: 33213829
Int Immunopharmacol. 2021 Apr;93:107407
pubmed: 33631512
Cytotherapy. 2021 Oct;23(10):861-873
pubmed: 34053857
Stem Cell Res Ther. 2020 Aug 18;11(1):361
pubmed: 32811531
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Postgrad Med. 2021 Nov;133(8):899-911
pubmed: 34470540
Int J Hematol. 2021 Jan;113(1):45-57
pubmed: 33161508
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
J Mol Histol. 2020 Dec;51(6):613-628
pubmed: 33011887
Signal Transduct Target Ther. 2021 Dec 10;6(1):418
pubmed: 34893580
Air Med J. 2021 Sep-Oct;40(5):298-302
pubmed: 34535232
Pediatr Blood Cancer. 2019 Jul;66(7):e27747
pubmed: 30968531
Acta Pharmacol Sin. 2023 Apr;44(4):695-709
pubmed: 36253560
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Vaccines (Basel). 2022 Jan 17;10(1):
pubmed: 35062796
Hematol Transfus Cell Ther. 2022 Apr-Jun;44(2):218-224
pubmed: 35098036
Respir Physiol Neurobiol. 2020 Sep;280:103492
pubmed: 32659271